| __timestamp | Alnylam Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 8185000 |
| Thursday, January 1, 2015 | 60610000 | 8871000 |
| Friday, January 1, 2016 | 89354000 | 9645000 |
| Sunday, January 1, 2017 | 199365000 | 12387000 |
| Monday, January 1, 2018 | 382359000 | 14381000 |
| Tuesday, January 1, 2019 | 479005000 | 19238000 |
| Wednesday, January 1, 2020 | 588420000 | 17425000 |
| Friday, January 1, 2021 | 620639000 | 23040000 |
| Saturday, January 1, 2022 | 770658000 | 25116000 |
| Sunday, January 1, 2023 | 795646000 | 51953000 |
| Monday, January 1, 2024 | 975526000 |
In pursuit of knowledge
In the dynamic world of biotechnology, managing operational costs is crucial for sustaining innovation and growth. Alnylam Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Alnylam's Selling, General, and Administrative (SG&A) expenses surged by over 1,600%, reflecting its aggressive expansion and investment in groundbreaking therapies. In contrast, CymaBay's SG&A expenses grew by approximately 535%, indicating a more measured approach.
Alnylam's expenses peaked in 2023, reaching nearly 800 million, a testament to its commitment to scaling operations. Meanwhile, CymaBay's expenses, though significantly lower, saw a notable increase in 2023, suggesting strategic shifts. This divergence highlights the varied strategies biotech firms employ to navigate the competitive landscape. As these companies continue to evolve, their financial strategies will remain pivotal in shaping their future trajectories.
AbbVie Inc. or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
SG&A Efficiency Analysis: Comparing Pharming Group N.V. and CymaBay Therapeutics, Inc.
Grifols, S.A. and CymaBay Therapeutics, Inc.: SG&A Spending Patterns Compared
Alpine Immune Sciences, Inc. or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
CymaBay Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared